AbbVie Receives An Upgrade From Vetr
On Tuesday, the Vetr crowd upgraded their rating for AbbVie Inc (NYSE: ABBV), from 3 stars (Hold), issued four days ago, to 4.5 stars (Strong Buy). At the time of the upgrade, crowd sentiment for AbbVie was generally positive, with 63 percent of Vetr user ratings bullish.
Share price in the biopharma company has been trending up since mid-February, gaining over 8.5 percent. In that span, AbbVie released a solid Q4 earnings report, meeting an EPS estimates and just missing revenue estimates. The stock also picked up an upgrade from Goldman Sachs who put the stock at Buy.
By today's close, AbbVie was down slightly on the day at $65.67
Learn how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for AbbVie is up at $74.72, which is above the average analyst target price of $70.33. Less than 2 percent of Vetr users are holding ABBV in their watch lists
Latest Ratings for ABBV
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2021 | SVB Leerink | Maintains | Outperform | |
| Jan 2021 | Morgan Stanley | Maintains | Overweight | |
| Dec 2020 | SVB Leerink | Maintains | Outperform |
View More Analyst Ratings for ABBV
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: VetrBiotech Upgrades Price Target Crowdsourcing Analyst Ratings
